O’Neil Health Care Weekly

XLV gained 88bps last week but is still facing resistance at the August high of $134.47. The next level above that is
~$137.50. Support remains the flattened 200-DMA ($130.16). Though the relative strength line rallied from oversold levels,
it remains well off highs, warranting an equal to slightly overweight sector positioning. Overall, despite the two-week lag,
this ETF still looks intact on an absolute basis as its one of few trading above all key moving averages.

Market View

The U.S. market remains in a Confirmed Uptrend. The S&P 500 rallied from 100-DMA (3,918) support this week to close just below logical near-term resistance at its rolling 200-DMA (4,057). Resistance above this level is the September high of 4,119. The Nasdaq, which is trading ~30% off highs, held 50-DMA (10,907) support despite still trading below near-term resistance at it 100-DMA (11,510). Resistance above this level is the falling 200-DMA (12,094). The distribution day count stands at six and two, respectively, with two days expiring on the S&P 500 and one on the Nasdaq next week.

O’Neil Health Care Weekly

XLV gained 88bps last week but is still facing resistance at the August high of $134.47. The next level above that is
~$137.50. Support remains the flattened 200-DMA ($130.16). Though the relative strength line rallied from oversold levels,
it remains well off highs, warranting an equal to slightly overweight sector positioning. Overall, despite the two-week lag,
this ETF still looks intact on an absolute basis as its one of few trading above all key moving averages.

Market View

The U.S. market remains in a Confirmed Uptrend. The S&P 500 and Nasdaq pulled back this week, consolidating
very sharp one-week gains above near-term support at the 100-DMA (3,910) and 50-DMA (10,956), respectively. The S&P
500 still faces resistance at the rolling 200-DMA (4,067) followed by the September high of 4,119. The Nasdaq touched
100-DMA (11,511) resistance Tuesday before pulling back to support over the last three sessions. The distribution day
count stands at six and two, respectively

Market View

The U.S. market is in a Confirmed Uptrend. The S&P 500 and Nasdaq gapped up 6% and 8% respectively this week and regained key levels of resistance. The S&P 500 is trading above its 100-DMA (3,904) for the first time since early September and quickly approaching the next level of resistance at its 200-DMA (4,081). The Nasdaq broke through its 50-DMA (11,014) and October highs (11,210) but will face resistance at its 100-DMA (11,518). The distribution day count stands at five and two respectively.

O’Neil Health Care Weekly

XLV declined 1.5% last week, consolidating strong 4-week gains just above 200-DMA ($130) support. The 50-DMA is
trading at $126.35. Resistance is $134.47. The relative strength line (vs. S&P 500) continues to rise, still warranting an
overweight sector positioning.

Market View

The U.S. market remains in an Uptrend Under Pressure. The S&P 500 and Nasdaq pulled back sharply from resistance at their 100-DMA (3,897) and 50-DMA (11,123) respectively. Indices are back below all key moving averages as the distribution day count has increased to four and two. The market status will be downgraded to a Downtrend should the S&P 500 close below the follow through day low (3,647) however price support is not until YTD lows at 3,491 and 10,088 respectively.

Market View

 

The U.S. market remains in a Confirmed Uptrend. The S&P 500 and Nasdaq rallied for a second straight week, progressing instantly higher post the October 21 follow-through day (FTD). The S&P 500 closed above its 50-DMA (3,842), which will now act as initial near-term support, while the 100-DMA (3,903) is now the next level of logical resistance. The Nasdaq is still trading below both the early October high of 11,230 and the rolling 50-DMA (11,314), which will coincide to act as near-term resistance. The distribution day count stands at two, and one, respectively.